
JNPMEDI, a clinical trial consulting and platform company, announced on the 30th that its revenue increased by 500% last year due to the expansion of its contract research organization (CRO) business and consulting services. This growth is attributed to the successful execution of key projects based on customized IP strategies and legal risk management.
When Korean bio companies enter overseas markets, they face risks such as patent litigation. Beyond litigation costs, failure to protect technology can lead to a decline in market share, making thorough preparation essential. Cases of Korean bio companies engaging in patent lawsuits in the United States, including those before the U.S. International Trade Commission (ITC), are increasing.
To address these challenges, JNPMEDI hired Director JaeHyun Lee, a former attorney at Kim & Chang, last year and established a dedicated team. The company develops customized strategies that consider the characteristics of each business and market environment while conducting legal reviews from the early development stage to proactively mitigate potential risks in each project.
JNPMEDI has also built a global-level compliance system to manage the increasingly complex regulatory environment and legal risks in the healthcare sector. In particular, it operates a legal risk hotline to provide prompt responses to issues. As a result of these efforts, the company secured new projects and clients last year, leading to a 200% increase in the number of contracts compared to the previous year.
A JNPMEDI representative stated, "The number of Korean medical device companies facing patent litigation in the U.S. is increasing. Companies must thoroughly secure patents and manage documentation from the early development stage. In major lawsuits, including ITC cases, well-organized documents and data play a critical role in determining the outcome."
✔️ Original Article : https://m.etnews.com/20250130000049
JNPMEDI, a clinical trial consulting and platform company, announced on the 30th that its revenue increased by 500% last year due to the expansion of its contract research organization (CRO) business and consulting services. This growth is attributed to the successful execution of key projects based on customized IP strategies and legal risk management.
When Korean bio companies enter overseas markets, they face risks such as patent litigation. Beyond litigation costs, failure to protect technology can lead to a decline in market share, making thorough preparation essential. Cases of Korean bio companies engaging in patent lawsuits in the United States, including those before the U.S. International Trade Commission (ITC), are increasing.
To address these challenges, JNPMEDI hired Director JaeHyun Lee, a former attorney at Kim & Chang, last year and established a dedicated team. The company develops customized strategies that consider the characteristics of each business and market environment while conducting legal reviews from the early development stage to proactively mitigate potential risks in each project.
JNPMEDI has also built a global-level compliance system to manage the increasingly complex regulatory environment and legal risks in the healthcare sector. In particular, it operates a legal risk hotline to provide prompt responses to issues. As a result of these efforts, the company secured new projects and clients last year, leading to a 200% increase in the number of contracts compared to the previous year.
A JNPMEDI representative stated, "The number of Korean medical device companies facing patent litigation in the U.S. is increasing. Companies must thoroughly secure patents and manage documentation from the early development stage. In major lawsuits, including ITC cases, well-organized documents and data play a critical role in determining the outcome."
✔️ Original Article : https://m.etnews.com/20250130000049